Where are the business opportunities under the long-term pharmaceutical policy reform?

Recently, the National Health and Health Commission Of the Department of Medicine in 2020 work points in the industry spread"Key points of work" mentioned that the future will further promote the implementation of the national basic drug system, the shortage of drugs to ensure stable prices, increase the encouragement of the development of generic drugs, and continuously improve the ability of drug administrationThe road is long and long, and there are still many problems to be solved on the road of drug reform, generic drugs to encourage production, the effect is poor
in order to solve the field of generic drugs, low concentration of industry, homogenization competition, low utilization rate of pharmaceutical capacity, in October 2019, the Health and Reform Commission announced the first batch of incentives for generic drugs, a total of 33 varieties, mainly related to anti-cancer drugs, rare disease drugs, antimalarial drugs and other drugs, most of which have expired or have not yet been registered for clinical supplyon the one hand, the state has a catalogue to encourage generic drugs, and some patents that expire in the high-priced pharmaceutical dividends will end;the problem is that this policy does not encourage generics significantly enoughby the Ameida public hospital sample statistics, compared with the 2019 sales of TOP5 "hot generic" declared quantity and 2019 sales of TOP5 "encourage dupressomy", in October-December 2019 declared quantity:data source: Ameda sample public hospital database, drug intelligenceencourage the introduction of the policy with in the three months after the introduction of the most popular generic drugs, no enterprises to declare the highest sales of 5 popular generic drugsOctober-December 2019, only 10 of the 33 drugs on the list of 33 incentives to be newly declared:data sources: Ameda Sample Public Hospital Database, Pharmacological Networkshows that, as things stand, policy encouragement is not obvious for generic sellingAlthough the epidemic, the rise in the price of RAW materials and other factors may affect the enterprise's generic declaration, but the core of the problem is that the incentive mechanism is not attractive to enterprises, not enough to drive the enterprise research and development productionwith the comprehensive development of clinical evaluation of drugs, the second batch of incentive drug imitation catalog is also in preparation, more attention to major diseases and rare diseases, special groups of people and other market-driven clinical drugsIt can be seen that the country's layout in the field of generic drugs is still in the process of implementation, and will continue to be continuedsecond, shortage of drugs - the establishment of word-of-mouth plus transformation and upgrading in recent years, there has been a shortage of drugs some production for many years, not in the patent protection period of drugs, the production process is relatively simple but the market demand is not large, coupled with production line adjustment, raw material procurement, product sales, logistics and transportation problems, making it difficult for pharmaceutical companies to make a profit, thus giving up the production of the drug, become a shortage of drugs overall, these high-quality drugs are low in profit, enterprises lack the enthusiasm to produce, but belong to the market in urgent need of varieties in order to solve this problem, at the end of April this year, the National Health and Reform Commission issued the "National Shortage Drug List Management Measures (Trial)", proposed to develop a list of shortage drugs, the list of drugs, allowing enterprises in the provincial drug centralized procurement platform independent quotation, direct lying on the net, independent procurement of medical institutions; Let the market mechanism play a leading role in the shortage of medicinesupply to ensure the reasonable profits of enterprises on the one hand, leave as much space as possible in price negotiations to give companies the opportunity to deal with risks On the other hand, enterprises also need to prepare countermeasures in advance, draw up plans to deal with the epidemic accelerated under the cost of raw materials, logistics, labor and so on for enterprises in need of transformation, such as a variety of auxiliary drugs or pharmaceutical enterprises, can fully seize the shortage of drug supply, and policy incentives, increase the shortage of drug development input or expand the shortage of drug production, in the establishment of social reputation at the same time, actively promote enterprises to upgrade, choose suitable areas of innovation, and finally complete the transformation of word-of-mouth and development third, urban and rural medical resources allocation is uneven, enterprises do a good job of channel sinking at the same time, in order to further implement the drug security system, to solve the problems of the masses difficult to see a doctor, expensive to see a doctor, "work points" put forward: to guide the local basic drug system marriage pilot, encourage urban medical groups and county medical community to establish a unified drug catalog and supply guarantee mechanism, promote the lower and lower medical institutions drug access We will promote the management of the use of this medicine in public medical institutions, and further enhance the proportion of essential drug use because of the uneven allocation of medical resources between urban hospitals and township hospitals, large hospitals and lower hospitals, there are many key points that need to be solved urgently in the unified drug catalogue, mainly reflected in the following aspects: 1 Some primary medical institutions lack adequate funds, old equipment, aging, few types of drugs, and lack of sufficient space to meet the needs of departments, drug warehouses
2 The scope and proportion of rural cooperative medical care in various regions are different, not conducive to unified management 3.The primary medicine habits and the base drug varieties are not adapted, drug distribution is not in place, drug shortages occur Mobile mechanism, primary medical institutions in the technical personnel, personnel structure, overall quality and other aspects of the need for comprehensive optimization 5 High-end medical equipment is mainly concentrated in large medical institutions, information is not fully shared, affecting patientexpectations and medical choices
reference to the four ways to solve such problems before: medical complex, medical community, specialized alliance, telemedicine, it is expected that the future may be in the following directions to develop more detailed programs: more reasonable and effective allocation of medical budget, increase financial input To promote the construction of hospital information, through the construction of information technology to shorten the gap, may be through the network of teaching, network medical and other ways, electronic appointment, tele-training, medical advice, the use of mobile medical, telemedicine and other ways to promote the sinking of high-quality medical resources, expand the coverage of medical services, reduce the uneven distribution of medical resources Further play the bottom-up role of the government mechanism, improve the management function, weaken the market brought about by the uneven allocation of resources
in general, in order to solve the problem of uneven medical allocation, in the future concrete implementation of the detailed rules, but also need to achieve policy support, technical support, capital investment of the trinity, joint attack iv, the basic drug catalogue and the medical insurance catalogue on the basic drug catalogue and the pharmaceutical catalog, the relevant person in charge of the National Health and Reform Commission has pointed out that the basic drugs and medical insurance drugs in the safe and effective, cost-effective ratio is not significantly different, but the basic drugs in the "prevention and control necessary, guarantee supply, priority use" in the property is stronger First, base drugs not only take into account clinical necessity, but also public health imperatives, including immunization programmes, anti-AIDS and tuberculosis drugs second, the base drug needs to take a variety of ways to ensure effective supply, to ensure continuous supply, the government through fixed-point, reserve and other means to ensure production and supply, through special financial funds or into the medical insurance fund to provide a high level of protection, improve the affordability of basic drugs for patients at the same time, , basic drugs are the first-line drugs of clinical choice and priority use, with the reform of medical insurance payment methods such as pay-per-disease payment and total advance payment, the guiding role of the basic drug catalogue will only be strengthened and will not be diluted from the point of view of ensuring supply and guiding clinical rational drug use the same, with the implementation of the base drug catalogue, the variety of basic drugs continue to increase, all areas still need to solve the township hospital storage space shortage, lack of funds, lack of personnel management and other issues for businesses, access to the base drug catalog of drugs, there is a great opportunity to enter the health insurance catalog This means that enterprises not only need to improve the safety and effectiveness of drugs and other measures to make products into the health insurance catalog, but also need to enter the Health and Reform Commission's basic drug catalog, close lying with the relevant policies, two-way preparation the long road of drug reform is long, long and long In view of these problems in the field of pharmaceuticals, the "Working Points" clearly define the future development of the focus, which drugs to take "unified management", which drugs to "market regulation." incentives are detours or shortcuts for businesses? This requires enterprises to strengthen the understanding of policy, understanding of the environment, combined with their own situation analysis and judgment, want to clearly go to where the future development, planning the short-term benefits and long-term benefits of the weight, seize the opportunity, when I do not wait.